{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:00:01Z","timestamp":1774393201400,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10549-025-07812-5","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:05:28Z","timestamp":1756397128000},"page":"247-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant response stratification based on complete, partial, and no response in HR-positive\/HER2-positive breast cancer"],"prefix":"10.1007","volume":"214","author":[{"given":"Ahmet Necati","family":"Sanli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Turan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz Esin","family":"Tekcan Sanli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isa","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Kadri","family":"Altundag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Aydogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"1","key":"7812_CR1","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"7692","key":"7812_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/d41586-018-01634-w","volume":"554","author":"DS Micalizzi","year":"2018","unstructured":"Micalizzi DS, Maheswaran S (2018) On the trail of invasive cells in breast cancer. Nature 554(7692):308\u2013309","journal-title":"Nature"},{"issue":"25","key":"7812_CR3","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","volume":"32","author":"F Ades","year":"2014","unstructured":"Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M (2014) Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 32(25):2794\u20132803","journal-title":"J Clin Oncol"},{"issue":"4","key":"7812_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40291-021-00525-7","volume":"25","author":"B Pellegrino","year":"2021","unstructured":"Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, Musolino A, Solinas C (2021) Luminal breast cancer: risk of recurrence and tumor-associated immune suppression. Mol Diagn Ther 25(4):409\u2013424","journal-title":"Mol Diagn Ther"},{"issue":"40","key":"7812_CR5","doi-asserted-by":"publisher","first-page":"65024","DOI":"10.18632\/oncotarget.11344","volume":"7","author":"ZH Li","year":"2016","unstructured":"Li ZH, Hu PH, Tu JH, Yu NS (2016) Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget 7(40):65024","journal-title":"Oncotarget"},{"issue":"1","key":"7812_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat A et al (2020) Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 21(1):33\u201343","journal-title":"Lancet Oncol"},{"issue":"4","key":"7812_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10238-019-00583-6","volume":"19","author":"N Babyshkina","year":"2019","unstructured":"Babyshkina N, Vtorushin S, Dronova T, Patalyak S, Slonimskaya E, Kzhyshkowska J, Cherdyntseva N, Choynzonov E (2019) Impact of estrogen receptor \u03b1 on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer. Clin Exp Med 19(4):547\u2013556","journal-title":"Clin Exp Med"},{"issue":"2","key":"7812_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G Von Minckwitz","year":"2017","unstructured":"Von Minckwitz G, Procter M, De Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A (2017) Adjuvant Pertuzumab and trastuzumab in early HER2-positive breast cancer. New England J Med 377(2):122\u2013131","journal-title":"New England J Med"},{"issue":"1","key":"7812_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-017-1299-9","volume":"16","author":"AA Hashmi","year":"2018","unstructured":"Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, Nisar M, Siddiqui M, Edhi MM, Faridi N, Khan A (2018) Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol 16(1):1","journal-title":"World J Surg Oncol"},{"issue":"15","key":"7812_CR10","doi-asserted-by":"publisher","first-page":"8077","DOI":"10.3390\/ijms25158077","volume":"25","author":"M Gonz\u00e1lez-Woge","year":"2024","unstructured":"Gonz\u00e1lez-Woge M et al (2024) The expression profiles of lncRNAs are associated with neoadjuvant chemotherapy resistance in locally advanced, luminal B-type breast cancer. Int J Mol Sci 25(15):8077","journal-title":"Int J Mol Sci"},{"issue":"4","key":"7812_CR11","first-page":"1735","volume":"24","author":"K Altundag","year":"2019","unstructured":"Altundag K (2019) Definition of luminal B HER-2-negative breast cancer subtype should be revisited. J Buon 24(4):1735","journal-title":"J Buon"},{"key":"7812_CR12","doi-asserted-by":"publisher","first-page":"45554","DOI":"10.1038\/srep45554","volume":"7","author":"G Gong","year":"2017","unstructured":"Gong G, Kwon MJ, Han J, Lee HJ, Lee SK, Lee JE, Lee SH, Park S, Choi JS, Cho SY, Ahn SH, Lee JW, Cho SR, Moon Y, Nam BH, Nam SJ, Choi YL, Shin YK (2017) A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+\/HER2- early breast cancer. Sci Rep 7:45554","journal-title":"Sci Rep"},{"issue":"3","key":"7812_CR13","first-page":"425","volume":"57","author":"J Rajc","year":"2018","unstructured":"Rajc J, Fr\u00f6hlich I, Mr\u010dela M, Toma\u0161 I, Flam J (2018) Prognostic impact of low estrogen and progesterone positivity in luminal B (Her2 negative) breast cancer. Acta Clin Croat 57(3):425\u2013433","journal-title":"Acta Clin Croat"},{"issue":"27","key":"7812_CR14","doi-asserted-by":"publisher","first-page":"1609972","DOI":"10.3389\/pore.2021.1609972","volume":"20","author":"S Tan","year":"2021","unstructured":"Tan S, Fu X, Xu S, Qiu P, Lv Z, Xu Y, Zhang Q (2021) Quantification of Ki67 change as a valid prognostic indicator of luminal B type breast cancer after neoadjuvant therapy. Pathol Oncol Res 20(27):1609972","journal-title":"Pathol Oncol Res"},{"issue":"9","key":"7812_CR15","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01610","volume":"40","author":"LJ Esserman","year":"2022","unstructured":"Esserman LJ, Berry DA, DeMichele A, Carey LA, Davis SE, Buxton MB et al (2022) Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 2 Trial. J Clin Oncol 40(9):956\u2013967. https:\/\/doi.org\/10.1200\/JCO.21.01610","journal-title":"J Clin Oncol"},{"issue":"7","key":"7812_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617\u2013628","journal-title":"N Engl J Med"},{"key":"7812_CR17","unstructured":"Winchester DJ, et al 2025 Member of the Ninth Edition AJCC Neoadjuvant Breast Expert Panel; TransSCOT Consortium. Novel Postneoadjuvant Prognostic Breast Cancer Staging System. J Clin Oncol. JCO2401739."},{"issue":"6","key":"7812_CR18","doi-asserted-by":"publisher","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with \u0131nitially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 156(6):e210891","journal-title":"JAMA Surg"},{"key":"7812_CR19","doi-asserted-by":"publisher","first-page":"5621441","DOI":"10.1155\/2022\/5621441","volume":"2022","author":"J Lv","year":"2022","unstructured":"Lv J, Ren J, Zheng J, Zhang F, Han M (2022) Prognosis of tumor microenvironment in luminal B-type breast cancer. Dis Markers 2022:5621441","journal-title":"Dis Markers"},{"issue":"3","key":"7812_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.21037\/tbcr-22-22","volume":"30","author":"EE Sereda","year":"2022","unstructured":"Sereda EE, Kolegova ES, Kakurina GV, Korshunov DA, Sidenko EA, Doroshenko AV, Slonimskaya EM, Kondakova IV (2022) Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes. Transl Breast Cancer Res 30(3):23","journal-title":"Transl Breast Cancer Res"},{"issue":"15","key":"7812_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12885-015-1207-z","volume":"29","author":"LC Tang","year":"2015","unstructured":"Tang LC, Jin X, Yang HY, He M, Chang H, Shao ZM, Di GH (2015) Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China. BMC Cancer 29(15):201","journal-title":"BMC Cancer"},{"issue":"1","key":"7812_CR22","doi-asserted-by":"publisher","first-page":"e1918160","DOI":"10.1001\/jamanetworkopen.2019.18160","volume":"3","author":"Y Li","year":"2020","unstructured":"Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y, Wang M, Yi Z, Li H, Li H, Ren G (2020) Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer. JAMA Netw Open 3(1):e1918160","journal-title":"JAMA Netw Open"},{"key":"7812_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah S, Chin SF et al (2012) The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486:346\u2013352","journal-title":"Nature"},{"key":"7812_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/DDDT.S336643","volume":"16","author":"ZH Li","year":"2022","unstructured":"Li ZH, Hu PH, Tu JH, Yu NS (2022) Prognostic significance of progesterone receptor status in breast cancer: a review and future directions. Drug Des Devel Ther 16:305\u2013318","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"7812_CR25","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1093\/jnci\/djae163","volume":"116","author":"W Chen","year":"2024","unstructured":"Chen W, Altshuler RD, Daschner P, Salvador Morales C, St Germain DC, Guida J, Prasanna PGS, Buchsbaum JC (2024) Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes. J Natl Cancer Inst 116(11):1730\u20131738","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"7812_CR26","doi-asserted-by":"publisher","first-page":"101831","DOI":"10.1016\/j.esmoop.2023.101831","volume":"8","author":"MA Benderra","year":"2023","unstructured":"Benderra MA, Serrano AG, Paillaud E, Tapia CM, Cudennec T, Choua\u00efd C, Lorisson E, de la Taille A, Laurent M, Brain E, Bringuier M, Gligorov J, Caillet P, Canoui-Poitr\u00efne F (2023) Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study. ESMO Open 8(5):101831","journal-title":"ESMO Open"},{"key":"7812_CR27","doi-asserted-by":"publisher","first-page":"usaf252","DOI":"10.1093\/milmed\/usaf252","volume":"9","author":"E Hulen","year":"2025","unstructured":"Hulen E, Zullig LL, Pleasant T, Wall R, Edwards ST, Ono S (2025) Attitudes towards mammography among rural-residing women veterans overdue for breast cancer screening. Mil Med 9:usaf252","journal-title":"Mil Med"},{"issue":"1","key":"7812_CR28","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1186\/s12885-025-14090-3","volume":"25","author":"JW Carew","year":"2025","unstructured":"Carew JW, Radulescu SC, Zhang L, Ungurean C, Calomfirescu C, Furtunescu F, Soliman AS (2025) Breast cancer mortality in Romania: trends, regional and rural-urban inequalities, and policy implications. BMC Cancer 25(1):1038","journal-title":"BMC Cancer"},{"issue":"1","key":"7812_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/biom15010078","volume":"15","author":"T Moura","year":"2025","unstructured":"Moura T, Caramelo O, Silva I, Silva S, Gon\u00e7alo M, Portilha MA, Moreira JN, Gil AM, Laranjeira P, Paiva A (2025) Early-stage luminal B-like breast cancer exhibits a more immunosuppressive tumor microenvironment than luminal a-like breast cancer. Biomolecules 15(1):78","journal-title":"Biomolecules"},{"issue":"9793","key":"7812_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771\u2013784","journal-title":"Lancet"},{"issue":"7","key":"7812_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/jnci\/djz213","volume":"112","author":"M Anurag","year":"2020","unstructured":"Anurag M, Zhu M, Huang C, Vasaikar S, Wang J, Hoog J, Burugu S, Gao D, Suman V, Zhang XH, Zhang B, Nielsen T, Ellis MJ (2020) Immune checkpoint profiles in luminal B breast cancer (Alliance). J Natl Cancer Inst 112(7):737\u2013746","journal-title":"J Natl Cancer Inst"},{"key":"7812_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-8751-1_2","volume":"1856","author":"RG Dumitrescu","year":"2018","unstructured":"Dumitrescu RG (2018) Interplay between genetic and epigenetic changes in breast cancer subtypes. Methods Mol Biol 1856:19\u201334","journal-title":"Methods Mol Biol"},{"issue":"1","key":"7812_CR33","doi-asserted-by":"publisher","first-page":"a041320","DOI":"10.1101\/cshperspect.a041320","volume":"14","author":"A Swarbrick","year":"2024","unstructured":"Swarbrick A, Fernandez-Martinez A, Perou CM (2024) Gene-expression profiling to decipher breast cancer inter- and intratumor heterogeneity. Cold Spring Harb Perspect Med 14(1):a041320","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"7812_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.21873\/anticanres.16786","volume":"44","author":"A Ozaki","year":"2024","unstructured":"Ozaki A, Matsuda A, Maemura Y, Tada Y, Kasai T, Nagashima Y, Onaga C, Hara Y, Kitabatake K, Tsukimoto M, Tamori S, Sasaki K, Ohno S, Akimoto K (2024) Luminal B breast cancer coexpressing p62 and ALDH1A3 Is less susceptible to radiotherapy. Anticancer Res 44(1):37\u201347","journal-title":"Anticancer Res"},{"issue":"10","key":"7812_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2217\/fon-2023-0083","volume":"19","author":"J Hou","year":"2023","unstructured":"Hou J, Li L, Wang J, Huang X, Xue J, Wu J (2023) Young age is associated with inferior outcomes in early-stage luminal B breast cancer patients who undergo mastectomy. Future Oncol 19(10):715\u2013726","journal-title":"Future Oncol"},{"issue":"4","key":"7812_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/tbj.14177","volume":"27","author":"Z Alaidy","year":"2021","unstructured":"Alaidy Z, Mohamed A, Euhus D (2021) Breast cancer progression when definitive surgery is delayed. Breast J 27(4):307\u2013313","journal-title":"Breast J"},{"issue":"1","key":"7812_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13058-023-01747-9","volume":"25","author":"SK Hung","year":"2023","unstructured":"Hung SK, Yang HJ, Lee MS, Liu DW, Chen LC, Chew CH, Lin CH, Lee CH, Li SC, Hong CL, Yu CC, Yu BH, Hsu FC, Chiou WY, Lin HY (2023) Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study. Breast Cancer Res 25(1):149","journal-title":"Breast Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07812-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T19:03:46Z","timestamp":1758827026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07812-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7812"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07812-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study utilized de-identified data from the SEER database, which is publicly available and maintains patient anonymity, ethical approval and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}